The tumor suppressor p53 exhibits a subset of cytosolic functions independent of nuclear transactivation, including activation of apoptosis through interactions with the apoptotic effector proteins BAX and BAK 1 . Activated effectors form oligomers within the outer mitochondrial membrane (OMM) and permeabilize it, thus resulting in the release of cytochrome c and other signaling molecules and the induction of apoptosis 2,3 .
a r t i c l e s residues (termed BCL-xL∆C 27 ) and a stabilized triple-mutant form of p53 DBD (hereafter referred to as p53 DBD 28 ). These p53 mutations affect buried residues and do not alter DNA binding 28 .
Titration of unlabeled p53 NTD into [ 15 N]BCL-xL∆C ( Fig. 2 ) caused CSPs for residues within the BCL-xL BH3-binding groove between α-helices 3 and 4 (α3 and α4) and within α2, α5 and α8 ( Fig. 2a and Supplementary Fig. 1 ). When we titrated unlabeled BCL-xL∆C into [ 15 N]p53 NTD (Fig. 3) , we observed CSPs for residues within TAD1 and, to a lesser extent, TAD2 of p53 ( Fig. 3a and Supplementary Fig. 2 ), thus confirming past reports [18] [19] [20] .
Titration of p53 DBD caused extensive but quantitatively more subtle CSPs in [ 15 N]BCL-xL∆C (Fig. 2b) , with effects on residues within α2 and α3, the BH3-binding groove, the hinge between α6 and α7, and the N terminus of the flexible loop between α1 and α2 (residues 21-84). Widespread CSPs suggested that conformational changes may accompany BCL-xL binding to p53 DBD, as reported previously 14 . Titration of unlabeled BCL-xL∆C into [ 15 N]p53 DBD defined a broad interface that, as shown by others 12, 14 , coincided with the DNA-binding surface of p53 (Fig. 3b,d) . Finally, unlabeled p53 TET did not induce CSPs in [ 15 N]BCL-xL∆C, thus indicating that these constructs did not interact ( Supplementary  Fig. 1 ).
NMR titrations with multidomain p53 constructs (bearing the DBD-stabilizing mutations described above), including p53 N-D (containing the NTD and DBD, residues 1-292) and p53 N-D-T (containing the NTD, DBD and TET, residues 1-360; Fig. 1) , revealed CSP patterns similar to those observed with individual domains. Titration of [ 15 N]BCL-xL∆C with p53 N-D caused CSPs similar to but larger than those observed with p53 NTD or p53 DBD (Fig. 2c) , whereas p53 N-D-T caused marked resonance broadening at high concentrations (Fig. 2d) . When we titrated unlabeled BCL-xL∆C into 2 H-and 15 N-labeled p53 N-D or N-D-T, CSPs within the NTD and DBD regions closely matched the perturbations observed in individual domains (Fig. 3c,e) .
We then used isothermal titration calorimetry (ITC) to determine the affinities of these interactions. Titrations between BCL-xL∆C and p53 constructs that contained the DBD exhibited weakly endothermic binding that approached the signal-to-noise limits of the calorimeter and precluded quantitative analysis. Titrations performed with a BCL-xL construct lacking the disordered α1-α2 loop (BCL-xL∆L∆C), however, exhibited exothermic binding suitable for quantitative analysis (Supplementary Table 1 and Supplementary Note). The change in binding enthalpy (∆H) upon deletion of the disordered BCL-xL loop suggested that this segment somehow participated in binding; however, qualitative comparison of titrations performed with BCL-xL∆C or BCL-xL∆L∆C indicated that it did not affect binding All the constructs that encompassed the DBD contained three buried core-stabilizing mutations (marked with asterisks) 28 . The color coding for various p53 domain constructs in this figure will be used throughout all figures. Table 1 ) than did p53 NTD (K d = 250 µM), both with 1:1 stoichiometry, and p53 TET did not bind BCL-xL. Linkage of p53 NTD and DBD (p53 N-D) did not dramatically enhance binding affinity compared to that of p53 DBD alone, thus indicating that, although p53 TAD1 and TAD2 transiently bound the BH3-binding groove of BCL-xL, they did not cooperate with the DBD to enhance affinity for BCL-xL. We next investigated the role of p53 TET within multidomain p53 constructs in BCL-xL binding. The limited solubility of p53 D-T (containing the DBD linked to TET) precluded its use in NMR experiments; however, ITC titrations showed that linkage of DBD and TET enhanced binding affinity for BCL-xL∆L∆C approximately one order of magnitude over that of p53 DBD (K d = 1.9 µM); p53 N-D-T showed a further increase in affinity for BCL-xL∆L∆C (K d = 0.6 µM). Both titrations exhibited 1:1 stoichiometry (BCL-xL∆L∆C/p53 construct monomer). NMR data confirmed the tetrameric state of p53 N-D-T 30 , and its concentration in ITC experiments (30 µM) exceeded the K d for p53 tetramers (<1 µM) 31 . These results supported that p53 tetramerization enhanced BCL-xL binding but also suggested that tetramerization did not affect the general mode of interaction, with BCL-xL binding 1:1 to individual N-D domains within tetrameric p53 N-D-T. BCL-xL∆C demonstrated that the two p53 constructs bound BCL-xL through a similar structural mechanism, involving primarily p53 DBD and secondarily p53 NTD interactions. CSPs were not present within the tetramerization domain of [ 15 N]p53 N-D-T, thus indicating that this domain has an indirect role in enhancing the affinity of p53 for BCL-xL. We reasoned that this enhancement of affinity is caused by increased local concentration of p53 DBD in the context of tetrameric p53 (Fig. 3f) .
Charge interactions drive BCL-xL-p53 complex formation
After establishing that p53 DBD primarily mediates binding to BCL-xL, we endeavored to determine the solution structure of the BCL-xL-p53 DBD complex. CSPs identified general contact interfaces but were insufficient to define the relative orientations of the two proteins. We therefore analyzed paramagnetic relaxation enhancement (PRE) effects on [ 15 N]p53 DBD upon addition of BCL-xL∆C constructs labeled with the nitroxide MTSL. We probed three labeling sites: wild-type Cys151 (Supplementary Fig. 3 Fig. 3 and Supplementary Note). We further detected a small number of intermolecular 1 H-1 H NOEs between amide protons of [ 2 H, 15 N]p53 DBD and the side chains of unlabeled BCL-xL∆C ( Supplementary  Fig. 4 ). Using distance restraints spanning the intermolecular interface, we determined the structure of the complex in two stages. First, recognizing, on the basis of our own and others' data 14 , that binding of p53 DBD alters the conformation of BCL-xL, we determined the structure of BCL-xL∆C, selectively labeled as above, when bound to unlabeled p53 DBD. We validated this structure-determination protocol 29 by determining the structure of apo-BCL-xL∆C When bound to p53 at substoichiometric concentrations, BCL-xL will have increased chances to reassociate with p53, which exhibits high local concentration in the tetrameric state, rather than to diffuse away and fully dissociate from the complex. Table 2 ). Second, we used the p53 DBD-bound BCL-xL structure and the crystal structure of p53 DBD (PDB 2AC0) 32 to determine the solution structure of the BCL-xL∆C-p53 DBD complex ( Fig. 4 and Table 3 ). The BCL-xL∆C-p53 DBD complex revealed highly charged interfaces, in agreement with the ionic-strength dependence of this interaction 14 . Interfacial residues on BCL-xL are found within the N terminus of the α1-α2 loop, within the α3-α4 and α5-α6 loops (as previously reported 12 ) and within the α2-α3 loop and α-helix 3. The interfacial residues within the p53 DBD are clustered in two major patches. One overlaps with the DNA-binding region and the other, encompassing α-helix 1 and the Zn 2+ -coordination site, is not directly involved in DNA binding but forms intermolecular DBD-DBD contacts when p53 binds to DNA 33 . At the complex interface, basic residues on the p53 DBD interact with acidic residues on BCL-xL. These interactions include those between the Zn 2+ -coordination site on the p53 DBD and Glu153 and Asp156 on BCL-xL, and between Arg248 on p53 and Asp158 on BCL-xL. Interactions also occur between acidic residues on p53 DBD and basic residues on BCL-xL (e.g., between Glu180 on p53 and Lys20 on BCL-xL, and between Arg103 on BCL-xL and Asp186 on BCL-xL). These contacts, with opposite charge complementarity as compared to the overall interface, probably determine the orientation of the two proteins. A few hydrophobic interactions engage residues within α3 of BCL-xL and Leu137 and Met237 within the p53 DBD (Supplementary Note).
The p53 DBD-bound conformation of BCL-xL∆C differed from its apo form in the N-terminal region of the α1-α2 loop; α2 was extended, and α3 was repositioned nearly perpendicular to α4 (Supplementary Fig. 5 ). These rearrangements affect a region of BCL-xL that is involved in binding to BH3-only proteins; consequently, we investigated whether the binding of p53 to BCL-xL modulated its interactions with BH3 domains. We measured by ITC the binding of a BID BH3-domain peptide to BCL-xL∆C that was simultaneously bound to different p53 constructs ( Table 1) . Preliminary binding of the p53 DBD to BCL-xL did not noticeably alter binding of BID to the BH3 groove of BCL-xL, which mediates most known antiapoptotic functions of BCL-xL 34 . In summary, the structure of the BCL-xL∆C-p53 complex illustrates how BCL-xL is able to sequester cytosolic p53 without altering its antiapoptotic functions involving interactions with BH3-only proapoptotic proteins.
Tuning p53 binding to DNA versus BCL-xL through mutagenesis
The structure of BCL-xL∆C-p53 DBD revealed that only a portion of the DBD surface engaged in BCL-xL binding is also used for DNA binding ( Fig. 5a-c) , thus suggesting the possibility to selectively disrupt the binding of p53 DBD to BCL-xL through mutagenesis. 
r t i c l e s
We mutated DBD residues within p53 N-D-T that were predicted 35, 36 or reported [37] [38] [39] to not disrupt domain folding and/or known to maintain transactivation function 40 ; some of these mutations have been observed in human cancers 35, 36 . We also mutated corresponding interacting residues on BCL-xL∆C (Fig. 5d) . We used fluorescence polarization to monitor binding of p53 mutants to fluorescein-labeled BCL-xL∆C (F-BCL-xL∆C); we measured binding of unlabeled BCLxL∆C mutants to wild-type p53 N-D-T, using this assay in a competition setting (Supplementary Fig. 6 ).
Individual mutations within the DBD of p53 N-D-T reduced affinities for BCL-xL by one to two orders of magnitude, thus supporting our structural model. We observed the largest effects for mutation of K120E and of H178D. Lys120 is located in a region of p53 DBD where BCL-xL and DNA interfaces overlap, whereas His178 occupies a position that principally contributes to BCL-xL binding. The combination of a second mutation (E180K) with H178D resulted in a reduction by over two orders of magnitude in BCL-xL binding affinity. Individual mutations within BCL-xL reduced affinity for p53 N-D-T about one order of magnitude; binding could not be detected for two dual mutants (I114A combined with either K20A or E158K). These results further support our structural model of the BCL-xL∆C-p53 DBD complex ( Fig. 5 and Supplementary Table 2) .
We also measured binding of wild-type and mutated p53 N-D-T to fluorescently labeled DNA oligonucleotides encoding the promoter sequences from the genes encoding p21 and puma ( Fig. 5;  Supplementary Table 3 and Supplementary Fig. 7) . We fit binding curves to a cooperative binding model assuming equal affinities of p53 DBD for the two suboptimal consensus sites within each promoter. This basic analysis indicated that wild-type p53 N-D-T bound both oligonucleotides with high affinity (apparent K d < 6.4 nM and Hill coefficient ≈2, thus indicating cooperative binding of p53 tetramers), in agreement with previous reports 41 . The R248Q cancer mutation 42 impaired binding to both DNA sequences; K120E or C277W mutations primarily impaired binding to the puma promoter. Acetylation of Lys120 (refs. 43,44) and mutation of Cys277 (ref. 38 ) are known to alter p53 DNA binding specificities, consistently with this selective effect. Mutations outside the DNA interface, including the H178D E180K double mutant, that bound BCL-xL very weakly also bound DNA tightly but with low cooperativity, probably because the mutated residues are involved in DBD-DBD contacts that stabilize interactions between dimeric or tetrameric p53 DBD units and DNA 33 .
To confirm the overlapping and mutually exclusive nature of interaction sites for DNA and BCL-xL on the p53 surface, we verified that a nonfluorescent p21 promoter oligonucleotide competitively inhibited formation of the complex between F-BCL-xL∆C and wild-type p53 N-D-T. Importantly, p53 N-D-T and full-length, wild-type human p53 (Bac-p53) exhibited equivalent affinities for F-BCL-xL∆C and DNA oligonucleotides, thus ruling out potential interferences of the core-stabilizing mutations on NMR experiments and binding assays ( Supplementary Figs. 6 and 7) .
Collectively these experiments demonstrate that mutation of p53 residues that are involved in binding to both DNA and BCL-xL disrupted both interactions, whereas mutation of residues that principally contact BCL-xL predominantly disrupted interactions with BCL-xL with limited effects on DNA binding. The DNA binding affinities of p53 mutants also correlated with transactivation activities measured in a yeast reporter assay 40 (Supplementary Fig. 8) , thus indicating that mutagenesis may help discriminate between the nuclear and cytosolic functions of p53.
Modulation of cytosolic p53 function through mutagenesis
The knowledge gained from in vitro mutagenesis experiments allowed us to selectively manipulate the apoptotic signaling axis of cytosolic p53. First, we evaluated the cellular functionality of p53 mutants that showed low affinity for BCL-xL but retained partial DNA binding in vitro. However, these experiments indicated that in vitro binding results predicted some but not all cellular behaviors of the p53 mutants. This outcome could be due to several factors, including the potential for p53 mutants to exhibit altered aggregation propensity in cells (possibly because of the lack of enhanced stability conferred by the stabilizing mutations) and to experience altered interactions with other protein partners 24, 25 , including activating interactions with BAX-BAK.
In agreement with in vitro BCL-xL binding assays, bindingdeficient p53 mutants expressed in p53-null H1299 cells showed little coimmunoprecipitation with endogenous BCL-xL (Fig. 6a) . Most of these poorly BCL-xL-sequestered p53 mutants, however, did not activate transcription of p21 or puma, despite exhibiting near-wild-type DNA binding in vitro (Fig. 6b) . As a partial exception, p53 D186A significantly activated transcription of both genes (P = 0.0055 and 0.0036 for p21 and puma, respectively), although at lower levels than for wild-type p53. Additional experiments provided insights into these transactivation deficiencies; the K120E mutant was defective in nuclear localization (Supplementary Fig. 9 ), and the E180K mutant exhibited altered post-translational modification or proteolytic processing (Fig. 6a) . The double mutant, H178D E180K, exhibited weak DNA binding cooperativity in vitro (Supplementary Table 3) . 
Consistently with transactivation data, wildtype p53 and the D186A mutant were able to induce cell death (Fig. 6c) . Interestingly, the latter mutant, as compared to wild-type p53, was associated with slightly higher levels of apoptosis (~30% versus ~24% annexin V + ; P = 0.032), despite its lower transcriptional activity. Asp186 within p53 DBD is not known to be involved in other established protein-protein interactions [43] [44] [45] ; therefore, we attribute the increased apoptotic function of the D186A mutant to decreased sequestration of p53 by BCL-xL and concomitant enhanced access to BAX. Conversely, the failure of other mutants to induce apoptosis cannot be ascribed solely to their lack of nuclear transactivation because the same mutations may also alter other functions of p53, including activation of BAX or BAK in the cytosol. To evaluate this possibility, we determined the ability of wild-type and mutant p53 N-D-T to activate BAX and permeabilize model membranes that mimic the OMM (large unilamellar vesicles (LUVs)) 46, 47 . All of the p53 mutants (in the context of p53 N-D-T), as compared to wild-type p53, caused reduced BAX activation and membrane permeabilization, thus indicating a possible overlap between the contact regions of BCL-xL and BAX on p53 (Supplementary Fig. 8 ). These findings underscored the challenge of using mutagenesis to dissect the various nuclear and cytosolic functions of p53 that are mediated by largely overlapping regions of the protein surface.
To circumvent the complexities associated with mutating p53, we evaluated the effects of BCL-xL mutations on the ability to sequester p53 and inhibit BAX activation. Although BCL-xL is also a multifunctional protein, most of its activities are mediated by interactions of BH3 domain-containing proteins with its BH3-binding groove 29 .
The observation that p53 binds to BCL-xL via an alternative surface (vide supra) enabled interrogation of the contributions of these two independent binding surfaces to antiapoptotic BCL-xL function. We monitored LUV permeabilization upon BAX activation by p53 N-D-T in the absence or presence of wild-type or mutant BCL-xL∆C (Fig. 7a,b) . To prevent BAX inhibition through sequestration of its BH3 domain by BCL-xL 48 , we preincubated BCL-xL with either the BH3 domain of the apoptotic derepressor BAD or the smallmolecule inhibitor ABT-737 (ref. 49) . Because ABT-737 also binds to the BH3-binding groove of BCL-xL, we verified, using fluorescence polarization, that this interaction affected the binding of BCL-xL to p53 only marginally (F-BCL-xL∆C-p53 N-D-T, Supplementary Fig. 6) ). We also verified that all the BCL-xL mutants bound a BAX BH3-domain peptide with affinities comparable to that of wild-type BCL-xL (K d ~500 nM; Supplementary Note), thus confirming that the mutations selectively altered binding of BCL-xL to p53 without compromising binding to BH3 domains.
The p53 N-D-T construct caused BAX activation-dependent LUV permeabilization that was inhibited by wild-type BCL-xL∆C-BAD BH3 or by wild-type BCL-xL∆C-ABT-737. Inhibition of BAX activation was dramatically diminished by mutation of Lys20, His113 
r t i c l e s
and Ile114 of BCL-xL∆C and less so by mutation of Arg103, Phe105, Asp156 and Glu158, in approximate agreement with the effects of these mutations on p53 N-D-T binding. Mutation of Ile114 together with either Lys20 or Glu158 within BCL-xL∆C abrogated p53 binding and inhibition of BAX activation. In the absence of BAD BH3 or ABT-737, however, BCL-xL∆C mutants that displayed impaired protection when bound to these molecules were able to inhibit LUV permeabilization, owing to their unaltered ability to bind the BH3 domain of partially active BAX 48 (Supplementary Fig. 8 ). These results demonstrate that BCL-xL mutations that disrupted binding to p53 N-D-T also impaired the ability of BCL-xL to inhibit p53-stimulated BAX activation.
To confirm these findings, we transiently transfected HCT116 cells, expressing wild-type p53 (ref. 50) , with Cerulean-tagged, wild-type or mutant BCL-xL (Cer-BCL-xL) and subjected them to UV irradiation to activate and stabilize p53. This treatment induced apoptosis in the absence and presence of ABT-737 in mock-transfected cells (~62% annexin V + , Fig. 7c) , which was inhibited in Cerulean-positive cells expressing wild-type BCL-xL (~11% annexin V + regardless of ABT-737 treatment). Wild-type BCL-xL-ABT-737 complexes cannot sequester proapoptotic BH3 regions but can still bind p53 and inhibit p53 activation of BAX-BAK; strikingly, ABT-737 was insufficient to abrogate BCL-xL's antiapoptotic function. However, cells expressing mutant BCL-xL defective in p53 binding exhibited enhanced apoptosis compared to those expressing wild-type BCL-xL in the absence of ABT-737 and significantly higher levels of apoptosis when treated with ABT-737 (19% and 17% annexin V + without ABT-737 versus 42% and 44% annexin V + with ABT-737 for the Ile114 and Lys20 mutants, respectively; P = 0.0003 and P < 0.0001, respectively). We further used fluorescence imaging to monitor the viability of HCT116 cells transfected with the same BCL-xL reagents. This experiment, performed with longer incubation times than those in the previous assay, revealed differential cell death between samples transfected with wild-type or mutant BCL-xL both in the absence and presence of ABT-737 (Fig. 7d) . Coimmunoprecipitation demonstrated the dependence of these results on differential sequestration of p53 by wild-type or mutant BCL-xL constructs (Fig. 7e) . Treatment with ABT-737 decreased, but did not abrogate, coimmunoprecipitation of p53 with wild-type Cer-BCL-xL. In support of BCL-xL-dependent inhibition of BAX activation, BAX coimmunoprecipitated with all of the Cer-BCL-xL constructs, wild-type and mutant, and this interaction was nearly abrogated in the presence of ABT-737. Furthermore, the two BCL-xL mutants exhibited wild type-like affinity for the BH3 domains of BIM and BID and were equivalent to wild-type BCL-xL in inhibiting BIM-or BID-dependent BAX activation in LUV assays (Supplementary Note). Mutations designed to selectively disrupt p53 binding therefore did not alter the BH3-domain binding properties of BCL-xL. In ABT-737-treated cells, not only were BH3 domains released from the BCL-xL hydrophobic groove but binding and sequestration of cytosolic p53 by mutant BCL-xL were also impaired, thus providing multiple mechanisms for BAX activation. These results support the role of the surface of BCL-xL shown in our solution structure of the BCL-xL∆C-p53 DBD complex in inhibiting p53-dependent BAX activation and induction of apoptosis in human cells.
DISCUSSION
Past studies of BCL-xL-p53 interactions have dealt with individual p53 domains [12] [13] [14] [15] [18] [19] [20] without addressing how they synergize within the full-length protein to engage BCL-xL. Our results confirm that p53 DBD is thermodynamically dominant in mediating binding to BCL-xL and show that, although p53 NTD interacts weakly with the BH3 groove of BCL-xL, as previously reported [18] [19] [20] , it does 
Tetramerization of p53, however, indirectly enhances binding to BCL-xL by increasing the local concentration of DBDs. Our determination of the solution structure of the BCL-xL∆C-p53 DBD complex reveals the molecular basis for sequestration of p53 by BCL-xL to inhibit BAX-BAK activation. This knowledge aided in the elucidation of differential roles of BCL-xL in regulating apoptosis through protein-protein interactions mediated by its BH3-binding groove and its p53-binding surface. The interface between the two proteins buries 1,821 Å 2 of surface area, dominated by charged and hydrophilic (1,076 Å 2 ) versus hydrophobic (745 Å 2 ) amino acids. This situation arises because the BCL-xL surface recognizes the same region of p53 DBD used for binding DNA 33 . Although BCL-xL does not structurally mimic duplex DNA, charged residues on its surface engage p53 DBD residues that make contacts with bases or phosphate groups of promoter DNA. The electrostatic nature of the interaction patch that overlaps with the p53 DNA-binding surface, as well as contacts involving the Zn 2+ -coordination site in p53 and acidic residues in BCL-xL, results in a low interface hydrophobicity (−0.43 Kcal/residue calculated solvation energy, versus an average value of −0.26 Kcal/mol for heterodimeric complexes) 51 . These results define the structural and functional roles of different p53 domains in binding to BCL-xL.
The p53 DBD surface that engages BCL-xL is larger than that used to bind DNA, thus suggesting that it would be possible to modulate this interaction through p53 DBD mutagenesis without abrogating DNA binding. Efforts to selectively eliminate BCL-xL binding through mutagenesis, however, were confounded by additional effects on protein stability and/or other interactions mediated by the same region of p53 (refs. 24,25) . Additional functions affected may include the activation of BAX or BAK, previously reported to engage the DNAbinding domain of p53 (ref. 13) . Despite this caveat, the slightly higher levels of apoptosis induced by the D186A mutant, which is released from BCL-xL, reinforces the role of BCL-xL as an inhibitor of p53's cytosolic proapoptotic activity. This result suggests that decreased BCL-xL sequestration of this mutant compensates for its partial impairment in activation of both transcription and BAX, leading to efficient induction of apoptosis.
In contrast to the complexities associated with selectively disrupting p53 binding to BCL-xL, structure-based mutagenesis of BCL-xL selectively disrupted BCL-xL-p53 binding in vitro and in cells and also enhanced p53-dependent apoptosis without disrupting BCL-xL's functions associated with sequestration of BH3 domains 33 . In the absence of ABT-737, the equivalent inhibitory activities of wild-type and mutant BCL-xL constructs against BH3 domains over-rode their differential ability to bind and sequester UV-activated p53. In the presence of ABT-737 these antiapoptotic activities were inhibited, to reveal the differential p53 binding-related, antiapoptotic functions of wild-type versus mutant BCL-xL. In cells expressing wild-type BCL-xL, capable of sequestering cytosolic p53, the addition of ABT-737 was insufficient to abrogate its protective effects against UV-induced apoptosis. However, BCL-xL mutants with impaired p53 binding displayed markedly impaired antiapoptotic effects. These results underscore the activity of cytosolic p53 to mediate UV-induced apoptosis and the ability of BCL-xL to oppose this activity.
The BCL-xL-p53 DBD structure expands understanding of p53 DBD's binding and functional versatility: this domain exploits the same surfaces to bind diverse protein partners (for example, BCL-xL, 53BP1 (ref. 43) , 53BP2 (ref. 44 ) and SV40 (ref. 45)) or target DNA in different regulatory contexts. It is fascinating that the DBD, long thought to dominate p53's tumor-suppressor functions through its nuclear gene-regulatory activity [21] [22] [23] 52 , is also an instrument of apoptotic regulation in the cytosol. We have characterized the structural details of p53's interaction with BCL-xL and the part that this interaction plays in restraining UV-and p53-dependent BAX activation and apoptosis. Our data show that p53 functionally interacts with BAX, as shown previously 2 , but molecular details of these interactions are poorly understood. Future studies on the structural basis of this interaction, as well as that with the other apoptotic effector, BAK, will provide deeper understanding of p53's cytosolic, apoptotic regulatory network and its contributions to tumor suppression.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Reagents. Detailed information about reagents used in this study can be found in the Supplementary Note. Protein expression and purification. Detailed descriptions of recombinantprotein expression and purification procedures can be found in the Supplementary Note.
Briefly, all proteins were expressed in the Escherichia coli BL21(DE3) expression strain. Unlabeled proteins were expressed in LB medium and isotopically labeled proteins in MOPS minimal medium supplemented with the appropriate labeling reagents dissolved in H 2 O or D 2 O. Selective protonation of isoleucine, leucine and valine methyl moieties was performed according to established procedures 53 . To maximize the yield, the insoluble fraction of isotopically labeled [ 2 H, 13 C, 15 N]p53 N-D-T was recovered from inclusion bodies and refolded according to an established procedure 54 , then purified as described in the Supplementary Note. NMR spectroscopy. All samples for NMR experiments were prepared in 10 mM sodium phosphate, 40 mM NaCl, 2 mM DTT (or 5 mM DTT for 3D p53 DBD samples), and 0.01% NaN 3 , pH 7.0, unless otherwise specified. Sample concentrations were 100 µM for 15 N-TROSY chemical-shift titrations, 200 µM for 13 C-HSQC chemical-shift titrations, 0.5 mM (p53 DBD), 0.6-1 mM (free BCL-xL∆C) and 0.6 mM (BCL-xL∆C bound to unlabeled p53 DBD) for samples used for 3D experiments. Unlabeled sample components were added in 1.1 molar excess over the labeled component unless otherwise specified. All experiments were performed at 25 °C on 600-MHz or 800-MHz Bruker Avance spectrometers, both equipped with cryogenically cooled tripleresonance z-gradient probes. Data were processed with Bruker Topspin and analyzed with CARA 55 . Resonance assignments were derived from published assignments of each studied construct and confirmed and integrated with triple-resonance experiments as described in detail in Supplementary Note. For 3D NOESY experiments, A NOE mixing time of 120 ms was used, with the exception of 15 N-edited TROSY-NOESY spectra of [ 2 H, 15 N]p53 DBD (450 µM) in the absence or presence of 2:1 molar excess unlabeled BCL-xL∆C, collected over 24 scans, 2,048 × 40 × 192 increments with a NOE mixing time of 160 ms. For paramagnetic relaxation enhancement (PRE) experiments, a S-(2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl methanesulfonothioate) (MTSL) spin label was introduced on BCL-xL Cys151 or, after mutation of the latter to serine, on S2C and S122C mutants by addition of a 10:1 molar excess of the label dissolved in acetonitrile to BCL-xL samples in 25 mM Tris, and 100 mM NaCl, pH 7.5. Reaction mixtures were incubated at room temperature in the dark for 2 h, and this was followed by overnight incubation at 4 °C. Excess unreacted spin label was removed by extensive buffer exchange over a Centricon centrifugal device. NMR samples containing 100 µM [ 2 H, 15 N]p53 DBD and the various MTSL-labeled BCL-xL constructs (150 µM) were prepared in the standard NMR sample buffer (described above) lacking DTT. TROSY spectra relevant to the oxidized state of the spin label were acquired swiftly in ~1.5 h. This was followed by immediate addition of excess solid DTT (to a final concentration of ~10 mM), which allowed reduction of the spin label and stabilized the cysteine-rich p53 DBD. A reference TROSY spectrum was then acquired for each sample after the spin label had been reduced. For PRE experiments involving isotopically labeled BCL-xL (100 µM) and paramagnetic Co 2+ -labeled p53 DBD (150 µM), the TROSY spectra of these samples were referenced against identically prepared samples containing Zn 2+ -expressed p53 DBD. For 13 C-detected and methyl-region 13 C-HSQC PRE experiments, samples contained 0.6 mM [ 2 H, 13 C, 15 N]BCL-xL∆C with selective protonation of side chain methyl groups of isoleucine, leucine and valine in the presence of 1.1 molar excess Zn 2+ -or Co 2+ -expressed p53 DBD. Structure calculation. Solution structure of BCL-xL-free and p53-bound conformation. Calculations were performed with Cyana 56 for 100 structures with 10,000 annealing steps, the 20 top ranking structures being selected as output. Distance restraints were generated from lists of NOESY cross-peaks imported from CARA depositories with Caliba for restraint calibration and merging. The output restraint lists were inspected by comparison with actual NOESY spectra to check for incorrect integrations due to peak overlaps.
Dihedral restraints were generated with Talos 57 . Hydrogen-bond restraints were generated manually after inspection of the presence or absence of amidewater cross-peaks in NOESY spectra. The Ramachandran statistics for the two models, assessed with Procheck 58 , were as follows. For apo-BCL-xL: mostfavored regions, 68.1% of all residues (84.6% of structured residues, 1-27 and 86-196); additionally allowed regions, 25.5% (12.1%); generously allowed regions, 4.9% (2.2%); and disallowed regions, 1.5% (1.1%). For p53-bound BCL-xL: most-favored regions, 69.2% (86.3%); additionally allowed regions, 23.4% (9.8%); generously allowed regions, 6.4 (3.5%); and disallowed regions, 1.1% (0.3%).
Structure of BCL-xL-p53 DBD complex. Calculations were performed with the web-server version of Haddock 59 with default settings and unambiguous distance restraints. PRE distance restraints were defined according to the formula of PRE distance dependence 60 with error ranges accounting for the undefined distance between the paramagnetic center and the restraint location (Cα of the labeled residue) for MTSL-derived restraints. NOE restraints were assigned to the heavy atom attached to the involved protons and, on the basis of cross-peak intensity, defined as strong (1-7 Å) or weak (3-9 Å). Input structures were 'chain A' of the crystal structure of free p53 DBD (PDB 2OCJ) 61 or DNA-bound p53 DBD (PDB 2AC0) 32 and the top-ranking NMR solution structure of p53-bound BCL-xL. No noticeable difference was observed between calculations performed on free or DNA-bound p53 DBD input structures; however, the latter produced a slightly better energy score (−220.5 ± 2.1 versus −203.6 ± 7.5) and was therefore chosen for further refinement performed with the Haddock refinement function. This step, which reduced the output cluster size from 200 to 20 structures, was repeated for three iterations until no further improvement of the structure energy function was observed (final score = −257.6 ± 4.5). Interface properties and hydrophobicity were analyzed with the ProtorP 62 , ProFace 63 and MolSurfer 64 web servers. The Ramachandran statistics for the model were as follows: most-favored regions, 85.0%; additionally allowed regions, 13.8%; generously allowed regions, 0.7%; and disallowed regions, 0.5%.
Isothermal titration calorimetry.
All ITC experiments were performed over 19 injections of 2 µL each at 25 °C in 20 mM Tris, 40 mM NaCl, and 2 mM TCEP, pH 7.0, with a MicroCal ITC200 instrument. Data were analyzed with the MicroCal ITC plugins within the Origin suite (OriginLab). Titrations were performed in duplicate or triplicate. Detailed descriptions of conditions for each set of titrations are in Supplementary Note. Fluorescence polarization. The BCL-xL C151S S2C double mutant was labeled with 5-iodoacetamidofluorescein (5-IAF, Thermo Scientific) in its stock buffer (25 mM Tris, 200 mM NaCl, 1 mM EDTA, and 5 mM DTT, pH 7.0) according to the manufacturer's reaction protocol, in the presence of DTT. Excess unreacted dye was removed by extensive buffer exchange over a centrifugal device. Fluorescence polarization measurements were performed at 25 °C in 96-well plates on a PerkinElmer EnVision plate reader equipped with FITC excitation and emission filters. Instrument settings were optimized automatically. The buffer was the same as that used for ITC experiments. The concentration of fluorescent probe (F-BCL-xL∆C or DNA oligos) was 20 nM in all cases. For direct binding experiments, 1:1 serial dilutions of WT or mutant p53 1-360 were performed over the range of concentrations indicated in the relevant figure; for competition experiments between F-BCL-xL∆C and unlabeled BCL-xL mutants or p21 promoter oligonucleotide, the oligonucleotide or BCL-xL mutants were serially diluted (1:1) into a mix of 20 nM F-BCL-xL∆C and 1.5 µM p53 1-360. All samples were incubated at room temperature in the dark for 2 h before fluorescence readings. Titrations were fit to a Langmuir isotherm equation, and for DNA binding titrations by p53 a Hill coefficient (h) was further introduced to account for the cooperative effect of binding by p53 tetramers: fraction bound = 1/[1+(K d /conc) h ], where K d is the fitted dissociation constant, and conc is the variable concentration of the titrated species. Competition titrations were fit as described previously 29 . Fitting of each titration was performed on the average of three independent experiments.
Large unilamellar vesicle assay. The assay was performed according to established procedures 47 . Fluorescence readings were carried out at 37 °C npg
